ABBOTT PARK, In poor health., Dec. 23, 2024 — Abbott introduced immediately it has reached an settlement with DexCom, Inc. to settle all excellent patent disputes between the businesses in circumstances associated to steady glucose monitoring merchandise.

The settlement will outcome within the dismissal of all pending circumstances in courts and patent places of work worldwide. It additionally features a provision that the events is not going to litigate patent, commerce gown, and design rights disputes with one another for the subsequent 10 years. There are not any monetary funds related to the settlement from both Abbott or Dexcom.

Abbott considers this settlement a constructive improvement, because it permits the corporate to totally concentrate on supporting individuals with diabetes with its applied sciences and providers.

Particulars of the settlement are confidential.

About Abbott:
Abbott is a world healthcare chief that helps individuals dwell extra absolutely in any respect levels of life. Our portfolio of life-changing applied sciences spans the spectrum of healthcare, with main companies and merchandise in diagnostics, medical units, nutritionals and branded generic medicines. Our 114,000 colleagues serve individuals in additional than 160 international locations. Join with us at www.abbott.com and on LinkedIn, Fb, Instagram, X and YouTube.

For additional info: Abbott Media: Kate Dyer, (224) 668-9965; Abbott Monetary: Michael Comilla, (224) 668-1872